| (Values in U.S. Thousands) | Jan, 2026 | Jan, 2026 | Jan, 2026 | Jan, 2026 | Jan, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Exiqon As (EXQNF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Exiqon A/S is a custom treatment provider for cancer patients. The company is divided into three operating segments: Diagnostics, Pharma Services, and Life Sciences. The company's Diagnostics segment offers tests that better aid treatment courses for physicians to choose. Oncotech EDR Assays is a cellular diagnostic test that measures drug resistances. The results of the tests state whether a patient would be resistant to or a good candidate for certain chemotherapies. The product line addresses testing for lung, colorectal, ovarian, and endometrial cancers. One a diagnosis is made, a specific in vitro therapy is given. The Phrama Services maintains a catalogue of over 150,000 human tumors that it conducts research on with pharmaceutical company partnerships. The company uses its faculties to determine drug resistance and aptitude in treating certain cancers. The Pharma segment also offers diagnostic services. The Life Sciences segment offers products for the analysis of microRNA molecules. These products reveal genetic profiles to researches. The company sells to the pharmaceutical, diagnostic, and technology industries. It also serves biological academic and research institutions. Its product portfolio comprises of microRNA Research, RNA Research, DNA Research, Custom Oligos, and Other Reagents.